| Literature DB >> 33115820 |
Guido Di Dalmazi1, Giulio Maltoni2, Claudio Bongiorno1, Lorenzo Tucci1, Valeria Di Natale2, Simona Moscatiello1, Gilberto Laffi1, Andrea Pession2, Stefano Zucchini2, Uberto Pagotto3.
Abstract
INTRODUCTION: The COVID-19 pandemic forced the Italian government to issue extremely restrictive measures on daily activities since 11 March 2020 ('lockdown'), which may have influenced the metabolic control of type 1 diabetes mellitus (T1D). The aims of the study were to investigate continuous glucose monitoring (CGM) metrics in children and adults with T1D during lockdown and to identify their potentially related factors. RESEARCH DESIGN AND METHODS: We enrolled 130 consecutive patients with T1D (30 children (≤12 years), 24 teenagers (13-17 years), and 76 adults (≥18 years)) using either Dexcom or FreeStyle LibreCGM>70% during the study period, without hybrid closed-loop insulin pump. CGM metrics during the 20 days before and the 20 days after lockdown were calculated. By telephonic contact, we performed validated physical activity and perceived stress questionnaires.Entities:
Keywords: diabetes mellitus; type 1
Mesh:
Substances:
Year: 2020 PMID: 33115820 PMCID: PMC7594202 DOI: 10.1136/bmjdrc-2020-001664
Source DB: PubMed Journal: BMJ Open Diabetes Res Care ISSN: 2052-4897
Anthropometric and biochemical characteristics at baseline
| Children | Teenagers | Adults | P value | |
| Number of patients | 30 | 24 | 76 | |
| Age (years) | 8.8 (7.7–10.6) | 15.6 (14.2–16.8) | 45.0 (29.0–58.1) | <0.001 |
| Female, n (%) | 13 (43.3) | 9 (37.5) | 37 (48.7) | 0.611 |
| SDS-BMI or BMI* | −0.2 (−0.5 to 0.4) | 21.3 (19.8–23.1) | 24.7 (22.1–26.8) | n.a. |
| Diabetes duration (years) | 4.2 (2.3–6.5) | 7.2 (5.1–9.5) | 22.0 (14.3–30.8)† | <0.001 |
| Complications | ||||
| Any, n (%)‡ | 30 (100.0) | 24 (100.0) | 54 (71.1) | 0.016 |
| Diabetic retinopathy, n (%) | 0 (0.0) | 0 (0.0) | 12 (15.8) | |
| Diabetic neuropathy, n (%) | 0 (0.0) | 0 (0.0) | 2 (2.6) | |
| Diabetic foot, n (%) | 0 (0.0) | 0 (0.0) | 1 (1.3) | |
| >1 complication, n (%) | 0 (0.0) | 0 (0.0) | 7 (9.2) | |
| Dexcom/FreeStyle Libre users, n (%)§ | 28/2 (93.3/6.7) | 22/2 (91.7/8.3) | 35/41 (46.1/53.9)† | <0.001 |
| Patients under multiple daily injection therapy, n (%) | 12 (40.0) | 11 (45.8) | 63 (82.9)† | <0.001 |
| Mean insulin dose (U/kg/day) | 0.8 (0.6–0.8) | 0.8 (0.7–1) | 0.5 (0.4–0.6) | <0.001 |
| Glycated hemoglobin, mmol/mol | 57 (51–62) | 51 (46–57) | 56 (49–64) | 0.080 |
| During lockdown | ||||
| Patients receiving medical advice by telephone, n (%) | 6 (20.0) | 2 (8.0) | 8 (11.0) | 0.330 |
| Patients with severe hypoglycemia, n (%) | 0 (0.0) | 0 (0.0) | 1 (1.3) | n.a. |
| IPAQ: total physical activity/day, METs | 1440 (840–1920) | 1018 (480–3056) | 1680 (720–3180) | 0.524 |
| IPAQ: high-intensity physical activity/day, METs | 0 (0–320) | 180 (0–2880) | 440 (0–1560) | 0.104 |
| IPAQ: moderate physical activity/day, METs | 1440 (240–1680) | 100 (0–390)† | 480 (120–1080) | 0.001 |
| IPAQ: walking/day, METs | 0 (0–180) | 75 (0–428) | 350 (78–780)¶ | 0.001 |
| IPAQ: mean sitting time/day, hours | 4.0 (3.0–6.0) | 7.3 (5.0–8.6)¶ | 5.5 (4–7.8) | 0.005 |
| PSS: perceived stress | n.a. | n.a. | 14.5 (9.8–20) | n.a. |
| Patients employed in working activity | ||||
| No, n (%) | n.a. | n.a. | 36 (47.4) | n.a. |
| Yes, n (%) | n.a. | n.a. | 20 (26.3) | |
| Smart working at home, n (%) | n.a. | n.a. | 20 (26.3) |
Data are expressed as median with IQR in parentheses. Continuous variables were analyzed by one-way analysis of variance, and categorical variables were investigated by χ2 test. Pairwise comparisons were made after Bonferroni correction.
*In children, SDS-BMI was calculated instead of BMI, according to a previous publication.21
†P<0.05 vs other groups.
‡No diabetic retinopathy, no diabetic neuropathy, and no diabetic foot.
§The number of scans per day in FreeStyle Libre users was similar between prelockdown (mean±SD 11.0±4.5) and during lockdown (11.2±4.8) (p=0.658).
¶P<0.05 vs children.
BMI, body mass index; IPAQ, International Physical Activity Questionnaire–Short Form; MET, metabolic equivalent; n.a., not assessed; PSS, Perceived Stress Scale; SDS-BMI, SD score for body mass index.
Continuous glucose monitoring parameters before and after lockdown in Italy due to COVID-19 pandemic in children (≤12 years), teenagers (13–17 years), and adults (≥18 years)
| Children (≤12 years) | Teenagers (13–17 years) | Adults (≥18 years) | |||||||
| Prelockdown | During lockdown | P value | Prelockdown | During lockdown | P value | Prelockdown | During lockdown | P value | |
| Sensor use (%) | 96.5 (87.5–98.8) | 96.2 (89.3–98.2) | 0.937 | 97 (93.4–98.5) | 96.9 (91.4–98.6) | 0.198 | 95.1 (91–97.5) | 95 (88.4–97.8) | 0.279 |
| Mean glucose (mg/dL) | 181 (161–206) | 178 (162–199) | 0.237 | 168 (141–180) | 164 (139–178) | 0.354 | 164 (145–191) | 160 (141–175) | 0.001 |
| Median glucose (mg/dL) | 171 (153–196) | 170 (154–190) | 0.322 | 157 (135–172) | 154 (133–169) | 0.378 | 159 (137–189) | 154 (133–168) | <0.001 |
| GMI (%) | 7.7 (7.2–8.3) | 7.6 (7.2–8.1) | 0.237 | 7.4 (6.7–7.6) | 7.3 (6.6–7.6) | 0.354 | 7.3 (6.8–7.9) | 7.2 (6.7–7.5) | 0.001 |
| GMI (mmol/mol) | 60 (55–67) | 59 (55–65) | 0.237 | 57 (50–60) | 56 (49–59) | 0.354 | 56 (51–63) | 55 (50–59) | 0.001 |
| SD (SDglu) | 67.4 (58.6–74.8) | 64.3 (55.5–75.2) | 0.029 | 59.1 (48.6–66.9) | 55.9 (47.6–66.8) | 0.611 | 63 (54–70.9) | 59.6 (52.2–69.3) | 0.016 |
| Percent CV (%) | 37.4 (33.4–40.4) | 36.8 (33.1–39.6) | 0.069 | 36.3 (32.4–41.6) | 35.2 (32.2–39.5) | 0.862 | 36.6 (33.1–41.8) | 36.3 (33.4–42.3) | 0.842 |
| TIR (%) | 53.3 (39.8–62) | 53.8 (43.4–62.7) | 0.055 | 61 (50.8–72.4) | 60.6 (54.9–73.6) | 0.213 | 57.7 (43.5–67.3) | 61.3 (53.7–68.3) | <0.001 |
| TBR1 (%) | 1.2 (0.7–2.7) | 1.3 (0.5–1.8) | 0.072 | 1.6 (0.6–4.9) | 1.1 (0.4–4.2) | 0.823 | 2.5 (1.1–5.4) | 3 (1.2–5.7) | 0.019 |
| TBR2 (%) | 0.4 (0.0–0.8) | 0.3 (0–0.4) | 0.029 | 0.2 (0–0.7) | 0.1 (0.1–0.7) | 0.420 | 0.4 (0.1–1.7) | 0.5 (0.1–1.6) | 0.419 |
| TAR1 (%) | 28.1 (25.1–31.0) | 27.3 (24.3–32.9) | 0.886 | 24.4 (17.5–34.4) | 25.5 (16.4–32.4) | 0.414 | 26.5 (19.3–31.7) | 25.1 (19–29.4) | 0.001 |
| TAR2 (%) | 14.5 (9–26.3) | 14.6 (7.2–22.5) | 0.074 | 9.6 (4.3–15.2) | 7.4 (2.9–16.7) | 0.408 | 11.1 (4.5–19) | 7.8 (4.4–13) | 0.007 |
| Low Blood Glucose Index | 0.5 (0.3–0.9) | 0.5 (0.2–0.6) | 0.033 | 0.7 (0.2–1.3) | 0.5 (0.3–1.4) | 0.713 | 0.8 (0.4–1.7) | 0.8 (0.4–1.7) | 0.047 |
| High Blood Glucose Index | 10.3 (7.5–15) | 9.6 (7.4–13.7) | 0.101 | 8.3 (5–10.1) | 7.7 (4.2–10.3) | 0.399 | 8.3 (5.4–12.2) | 7.2 (4.9–9.5) | 0.002 |
Data are expressed as median with IQR in parentheses. P values refer to paired samples t-tests performed for each parameter in the three groups of patients divided by age range. TIR: 70–180 mg/dL, TBR1: 54–69 mg/dL, TBR2 <54 mg/dL, TAR1 180–250 mg/dL, TAR2 >250 mg/dL.
CV, coefficient of variation; GMI, glucose management indicator; SDglu, glucose SD; TAR, time above range; TBR, time below range; TIR, time in range.
Comparison among the three groups of adults identified by unsupervised clustering according to the difference in values of prelockdown and during lockdown of TIR (ΔTIR) and SD (ΔSDglu)
| Improved TIR and variability | Worsened variability | P value | |
| ΔTIR (%) | 32.9 (18.5–39.0)* | −5.0 (-8.8–4.0) | <0.001 |
| ΔSDglu (%) | −13.0 (−20.9 to −10.9) | 11.6 (7.4–18.9) | <0.001† |
| TIR prelockdown (%) | 44.6 (41.0–51.5)* | 66.6 (42.7–73.2) | 0.002 |
| TIR during lockdown (%) | 60.1 (56.6–64.7) | 62.7 (41.9–69.6) | 0.768 |
| SD prelockdown | 66.8 (64.7–75.3) | 55.1 (47.2–63.8)§ | 0.043 |
| SD during lockdown | 58.1 (56.3–62.7) | 61.7 (54.6–76.1) | 0.511 |
| Median glucose prelockdown (mg/dL) | 188 (171–192)* | 148 (129–190) | 0.016 |
| Median glucose during lockdown (mg/dL) | 159 (143–167) | 146 (127–181) | 0.914 |
| Age (years) | 56.8 (28.9–60.9) | 51.9 (42.5–58.5) | 0.003 |
| Female, n (%) | 11 (57.9) | 10 (52.6) | 0.491 |
| BMI (kg/m2) | 25.8 (22.3–27.8) | 24.5 (22.4–26.8) | 0.592 |
| Dexcom/FreeStyle Libre users, n (%) | 11/8 (57.9/42.1) | 7/12 (36.8/63.2) | 0.417 |
| Glycated hemoglobin (mmol/mol) | 58 (53–71) | 60 (55–66) | 0.031 |
| Diabetes duration (years) | 21.4 (15.6–39.4) | 24.4 (14.4–34.5) | 0.210 |
| Patients with severe hypoglycemia, n (%) | 1 (5.3) | 0 (0.0) | n.a. |
| IPAQ: total physical activity/day, METs | 3158 (1440–5700)* | 700 (420–870) | 0.009 |
| IPAQ: high-intensity physical activity/day, METs | 1520 (0–3780) | 0 (0–0) | 0.053 |
| IPAQ: moderate physical activity/day, METs | 810 (240–1680) | 440 (15–900) | 0.981 |
| IPAQ: walking/day, METs | 360 (113–1260) | 250 (28–563) | 0.143 |
| IPAQ: mean sitting time/day (hours) | 360 (165–454) | 345 (263–495) | 0.744 |
| PSS: perceived stress | 16 (10–21) | 18 (13–25)‡ | 0.020 |
| Patients working during lockdown | |||
| No, n (%) | 9 (47.4) | 7 (36.8) | 0.881 |
| Yes, n (%) | 4 (21.1) | 7 (36.8) | |
| Smart working, n (%) | 6 (31.6) | 5 (26.3) |
Data are expressed as median with IQR in parentheses. Pairwise comparisons were made after Bonferroni adjustment.
*P<0.05 vs all other groups.
†P<0.05 for all pairwise comparisons.
‡P<0.05 vs ‘improved variability’ group.
§P<0.05 vs ‘improved TIR and variability’ group.
BMI, body mass index; IPAQ, International Physical Activity Questionnaire–Short Form; MET, metabolic equivalent; n.a., not assessed; PSS, Perceived Stress Scale; SDglu, glucose SD; TIR, time in range.